Di Wu, Guoyuan Liu, Yufeng Liu, Hexige Saiyin, Chenji Wang, Zhen Wei, Wenjiao Zen, Danyang Liu, Qi Chen, Zhonghua Zhao, Liping Zou, Haojie Huang, Songmin Jiang, Long Yu – 30 June 2016 – Interplay between cell polarity module Scribble‐Lethal Giant Larvae‐Discs Large 1 (DLG1) and Yes‐associated protein (YAP) appears critical in tumor metastasis. We identified zinc finger protein 191 (ZNF191) as a metastasis suppressor acting through DLG‐YAP crosstalk in hepatocellular carcinoma (HCC).

Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud‐Ratti, Tarik Asselah – 28 June 2016 – Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon‐alpha (Peg‐IFN‐α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.

Adrian Reuben – 28 June 2016

Jannick Prentoe, Rodrigo Velázquez‐Moctezuma, Steven K.H. Foung, Mansun Law, Jens Bukh – 28 June 2016 – There are 3‐4 million new hepatitis C virus (HCV) infections yearly. The extensive intergenotypic sequence diversity of envelope proteins E1 and E2 of HCV and shielding of important epitopes by hypervariable region 1 (HVR1) of E2 are believed to be major hindrances to developing universally protective HCV vaccines.

Andrea A. Tooley, Seth Sweetser – 28 June 2016

Dinesh Ganapathy, Jasmohan S. Bajaj – 28 June 2016

Carilyn Wieland – 28 June 2016

Joanne R. Morling, Indra N. Guha – 28 June 2016

Jorge E. Sanchez, Kathleen E. Corey – 28 June 2016

Armand Abergel, Sophie Metivier, Didier Samuel, Deyuan Jiang, Kathryn Kersey, Phillip S. Pang, Evguenia Svarovskaia, Steven J. Knox, Veronique Loustaud‐Ratti, Tarik Asselah – 28 June 2016 – Genotype 4 hepatitis C virus (HCV) was considered difficult to treat in the era of pegylated interferon‐alpha (Peg‐IFN‐α) and ribavirin regimens. We evaluated the efficacy and safety of therapy with the nonstructural (NS) 5A inhibitor, ledipasvir, combined with the NS5B polymerase inhibitor, sofosbuvir, in patients with HCV genotype 4.